The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21
Science Advances · 2025
DOI: 10.1126/sciadv.adt3142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Suowen Xu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sc…. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Quinazolinones, Growth Differentiation Factor 15, Piperidines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Obesity is a debilitating global pandemic with a huge cost on health care due to it being a major underlying risk factor for several diseases. Therefore, there is an unmet medical need for pharmacological interventions to curb obesity. Here, we report that halofuginone, a Food and Drug Administration–approved anti-scleroderma and antiprotozoal drug, is a promising anti-obesity agent in preclinical mouse and pig models. Halofuginone suppressed food intake, increased energy expenditure, and resulted in weight loss in diet-induced obese mice while also alleviating insulin resistance and hepatic steatosis. Using molecular and pharmacological tools with transcriptomics, we identified that halofuginone increases fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) levels via activating integrated stress response. Using Gdf15 and Fgf21 knockout mice, we show that both hormones are necessary to elicit anti-obesity changes. Together, our study reports the beneficial metabolic effects of halofuginone and underscores its utility in treating obesity and its associated metabolic complications, which merits clinical assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, He…
- Anhui Provincial Key Laboratory of Metabolic Health and Panvascular Diseases, Hefei 230001, China.
- Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany.
- Institute of Endocrine and Metabolic Diseases, University of Science and Technology of China, Hefei 230001, China.
- The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
- Laboratory of Precision and Intelligent Chemistry, Department of Polymer Science and Engineering, University of Science and Technology of China, Hefei 230026, China.
ORCID-Profile: Suowen Xu, Zhenghong Liu, Tian Tian, Wenqi Zhao, Zhihua Wang, Mengyun Xu, Zhidan Zhang, Yanjun Yin, Meiming Su, Wenxiang Fang, Wenhao Pan, Shiyong Liu, Min-Dian Li, Peter J Little, Danielle Kamato, Dongdong Wang, Stefan Offermanns, John R Speakman, Jianping Weng
Zitieren
APA
Xu, S., Liu, Z., Tian, T., Zhao, W., Wang, Z., Liu, M., Xu, M., Zhang, F., Zhang, Z., Chen, M., Yin, Y., Su, M., Fang, W., Pan, W., Liu, S., Li, M. D., Little, P. J., Kamato, D., Zhang, S., …, & Weng, J. (2025). The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21. Science Advances. https://doi.org/10.1126/sciadv.adt3142
Vancouver
Xu S, Liu Z, Tian T, Zhao W, Wang Z, Liu M, et al. The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21. Science Advances. 2025. doi:10.1126/sciadv.adt3142
BibTeX
@article{Xu2025,
author = {Xu, Suowen and Liu, Zhenghong and Tian, Tian and Zhao, Wenqi and Wang, Zhihua and Liu, Monan and Xu, Mengyun and Zhang, Fanshun and Zhang, Zhidan and Chen, Meijie and Yin, Yanjun and Su, Meiming and Fang, Wenxiang and Pan, Wenhao and Liu, Shiyong and Li, Min-Dian and Little, Peter J and Kamato, Danielle and Zhang, Songyang and Wang, Dongdong and Offermanns, Stefan and Speakman, John R and Weng, Jianping},
title = {The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adt3142}
}
EUVIMED